IP Library Granted Patent US 11,850,269
Granted Patent B2
US 11,850,269 · App. 17/207,164 · Granted Dec 26, 2023

Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them

Inventor: Thomas Julius Borody (Five Dock, AU)
Assignee: Finch Therapeutics Holdings LLC
A61K35/741A61J1/1468A61K9/4891A61K35/24A61K35/74A61K35/742A61M3/02A61M3/0204A61M39/00A61P1/12C12N1/00C12N1/20A61B10/0038A61K9/4875A61K2035/115A61M5/142A61M31/00A61M39/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,850,269
App. No.
17/207,164
Granted
Dec 26, 2023
Kind
B2
Abstract

The present disclosure provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. Methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.

Claims (26)

1. A method, comprising:

obtaining a stool from a human donor, wherein the stool comprises a collection of fecal bacteria;

expanding the collection of fecal bacteria in a first culture medium without any pre-segregating out of any particular bacterial species;

expanding the collection of fecal bacteria in a second culture medium without any pre-segregating out of any particular bacterial species; and

combining the expanded fecal bacteria from the first and second culture media to produce a microbial composition.

2. The method of claim 1 , wherein the first and second culture media have different media compositions.

3. The method of claim 1 , wherein at least one of expanding the collection of fecal bacteria in a first culture medium and expanding the collection of fecal bacteria in a second culture medium occurs under anaerobic conditions.

4. The method of claim 1 , further comprising supplementing the first culture medium, the second culture medium or the microbial composition with a bacterial isolate.

5. The method of claim 1 , wherein the microbial composition comprises bacteria selected from the group consisting of Firmicutes, Bacteroides , and a combination thereof.

6. The method of claim 1 , wherein the collection of fecal bacteria is separated from rough particulate matter of the stool prior to expanding.

7. The method of claim 1 , further comprising formulating the microbial composition as a pharmaceutical composition.

8. The method of claim 7 , wherein the formulating comprises lyophilizing the microbial composition.

9. The method of claim 7 , wherein the formulating comprises encapsulating the microbial composition.

10. The method of claim 7 , wherein the pharmaceutical composition comprises a cryoprotectant.

11. A method of manufacturing a pharmaceutical composition, comprising:

culturing a fecal flora from a stool of a healthy human donor without any pre-segregating out of any particular bacterial species; and

formulating the pharmaceutical composition to include multiple bacterial species from the cultured fecal flora.

12. The method of claim 11 , wherein the culturing occurs under anaerobic conditions.

13. The method of claim 11 , further comprising mixing the bacteria from the cultured fecal flora with a bacterial isolate.

14. The method of claim 11 , wherein the cultured fecal flora comprises bacteria selected from the group consisting of Firmicutes, Bacteroides , and a combination thereof.

15. The method of claim 11 , wherein the formulating comprises lyophilizing the bacteria from the cultured fecal flora.

16. The method of claim 11 , wherein the formulating comprises encapsulating the bacteria from the cultured fecal flora.

17. The method of claim 11 , wherein the fecal flora is separated from rough particulate matter of the stool prior to culturing.

18. The method of claim 11 , wherein the pharmaceutical composition comprises a cryoprotectant.

19. The method of claim 11 , wherein the pharmaceutical composition comprises an antioxidant.

20. The method of claim 11 , wherein the method comprises culturing multiple fecal flora from stool of multiple healthy human donors, and formulating the pharmaceutical composition to include multiple bacterial species from the multiple cultured fecal flora.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2022
From: BORODY, THOMAS J.
To: CRESTOVO HOLDINGS, LLC
Reel/Frame 059901/0377 →
CHANGE OF NAME Recorded May 13, 2022
From: CRESTOVO HOLDINGS, LLC
To: FINCH THERAPEUTICS HOLDINGS LLC
Reel/Frame 060065/0557 →
Priority Claims (1)
AU 2010903474 · Aug 4, 2010 · national
Continuity (12)
Continuation 16109413 · Aug 22, 2018
Continuation 15975456 · May 9, 2018
Continuation 15950939 · Apr 11, 2018
Continuation 15782519 · Oct 12, 2017
Continuation 15093679 · Apr 7, 2016
Continuation 13813915
Provisional Application 61494363 · Jun 7, 2011
Provisional Application 61483487 · May 6, 2011
Provisional Application 61451087 · Mar 9, 2011
Provisional Application 61450099 · Mar 7, 2011
Related Publication 20210205375A1 · Jul 8, 2021
Related Publication 20220031764A9 · Feb 3, 2022